← All trials
NCT05597306
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 19, 2022
- Primary completion
- Nov 19, 2024
- Completion date
- Nov 19, 2025
- First posted
- Oct 28, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MiamiLead sponsor
- Imago BioSciencesCollaborator
- University of MiamiOverall official - principal investigator
- University of MiamiSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.